Airway microbial diversity is decreased in young children with cystic fibrosis compared to healthy controls but improved with CFTR modulation.
Cystic fibrosis
Epidemiology
Health sciences
Human microbiome
Infectious disease
Microbiology
Pediatrics
Pulmonary medicine
Respiratory system
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
11
10
2019
revised:
11
01
2020
accepted:
27
05
2020
entrez:
10
6
2020
pubmed:
10
6
2020
medline:
10
6
2020
Statut:
epublish
Résumé
Culture-independent next generation sequencing has identified diverse microbial communities within the cystic fibrosis (CF) airway. The study objective was to test for differences in the upper airway microbiome of children with CF and healthy controls and age-related differences in children with CF. Oropharyngeal swabs and clinical data were obtained from 25 children with CF and 50 healthy controls aged ≤6 years. Bacterial DNA was amplified and sequenced for the V4 region of 16S rRNA marker-gene. Alpha diversity was measured using operational taxonomic units (OTUs), Shannon diversity, and the inverse Simpson's index. Beta diversity was measured using Morisita-Horn and Bray-Curtis and Jaccard distances. General linear models were used for comparison of alpha diversity measures between groups to account for differences in demographics and exposures. Mixed effects general linear models were used for longitudinal comparisons 1) between children with CF of different ages and 2) between children with CF receiving CF transmembrane conductance regulator (CFTR) modulators, children with CF not receiving CFTR modulators, and healthy controls to adjust for repeated measures per subject. Children with CF were more likely to have received antibiotics in the prior year than healthy controls (92% vs 24%, p < 0.001). Controlling age, race, ethnicity, length of breastfeeding, and having siblings, children with CF had a lower richness than healthy controls: OTUs 62.1 vs 83, p = 0.022; and trended toward lower diversity: Shannon 2.09 vs 2.35, p = 0.057; inverse Simpson 5.7 vs 6.92, p = 0.118. Children with CF have lower bacterial diversity and different composition of organisms compared with healthy controls. This appears to start in early childhood, is possibly related to the use of antibiotics, and may be partially corrected with the use of CFTR modulators.
Sections du résumé
BACKGROUND
BACKGROUND
Culture-independent next generation sequencing has identified diverse microbial communities within the cystic fibrosis (CF) airway. The study objective was to test for differences in the upper airway microbiome of children with CF and healthy controls and age-related differences in children with CF.
METHODS
METHODS
Oropharyngeal swabs and clinical data were obtained from 25 children with CF and 50 healthy controls aged ≤6 years. Bacterial DNA was amplified and sequenced for the V4 region of 16S rRNA marker-gene. Alpha diversity was measured using operational taxonomic units (OTUs), Shannon diversity, and the inverse Simpson's index. Beta diversity was measured using Morisita-Horn and Bray-Curtis and Jaccard distances. General linear models were used for comparison of alpha diversity measures between groups to account for differences in demographics and exposures. Mixed effects general linear models were used for longitudinal comparisons 1) between children with CF of different ages and 2) between children with CF receiving CF transmembrane conductance regulator (CFTR) modulators, children with CF not receiving CFTR modulators, and healthy controls to adjust for repeated measures per subject.
RESULTS
RESULTS
Children with CF were more likely to have received antibiotics in the prior year than healthy controls (92% vs 24%, p < 0.001). Controlling age, race, ethnicity, length of breastfeeding, and having siblings, children with CF had a lower richness than healthy controls: OTUs 62.1 vs 83, p = 0.022; and trended toward lower diversity: Shannon 2.09 vs 2.35, p = 0.057; inverse Simpson 5.7 vs 6.92, p = 0.118.
CONCLUSIONS
CONCLUSIONS
Children with CF have lower bacterial diversity and different composition of organisms compared with healthy controls. This appears to start in early childhood, is possibly related to the use of antibiotics, and may be partially corrected with the use of CFTR modulators.
Identifiants
pubmed: 32514485
doi: 10.1016/j.heliyon.2020.e04104
pii: S2405-8440(20)30948-8
pii: e04104
pmc: PMC7267737
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e04104Subventions
Organisme : NHLBI NIH HHS
ID : K12 HL119994
Pays : United States
Organisme : NCATS NIH HHS
ID : R21 TR002513
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001876
Pays : United States
Informations de copyright
© 2020 The Author(s).
Références
Infect Immun. 2015 Oct;83(10):3838-46
pubmed: 26169276
Ann Am Thorac Soc. 2015 Feb;12(2):221-9
pubmed: 25474078
Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13769-74
pubmed: 22872870
Am J Respir Crit Care Med. 2017 Jun 15;195(12):1617-1628
pubmed: 28222269
Am J Respir Crit Care Med. 2016 Mar 1;193(5):504-15
pubmed: 26492486
Pediatr Pulmonol. 1996 May;21(5):267-75
pubmed: 8726151
Am J Respir Crit Care Med. 2014 Jul 15;190(2):175-84
pubmed: 24927234
PLoS Comput Biol. 2014 Apr 03;10(4):e1003531
pubmed: 24699258
Front Microbiol. 2018 May 22;9:1037
pubmed: 29872428
Appl Environ Microbiol. 2013 Sep;79(17):5112-20
pubmed: 23793624
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Cyst Fibros. 2013 Dec;12(6):786-9
pubmed: 23632449
Pediatr Pulmonol. 2010 Jun;45(6):569-77
pubmed: 20503282
Sci Rep. 2015 May 14;5:10241
pubmed: 25974282
J Cyst Fibros. 2019 Sep;18(5):646-652
pubmed: 30580994
J Pediatr. 2009 Dec;155(6 Suppl):S73-93
pubmed: 19914445
PLoS One. 2014 Dec 19;9(12):e109798
pubmed: 25526264
N Engl J Med. 1994 Sep 8;331(10):637-42
pubmed: 7503821
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
J Cyst Fibros. 2019 Jan;18(1):22-34
pubmed: 29934203
Am Rev Respir Dis. 1991 Aug;144(2):331-7
pubmed: 1859056
Genome Biol. 2014;15(12):550
pubmed: 25516281
Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5809-14
pubmed: 22451929
Am J Respir Crit Care Med. 2012 Nov 1;186(9):857-65
pubmed: 22904182
J Pediatr. 2002 Dec;141(6):811-7
pubmed: 12461498
J Clin Microbiol. 2015 Jul;53(7):2022-9
pubmed: 25878338
Eur Respir J. 2017 Mar 29;49(3):
pubmed: 28356374
N Engl J Med. 1996 Jul 18;335(3):179-88
pubmed: 8657217
Sci Rep. 2019 May 10;9(1):7234
pubmed: 31076617
PLoS Pathog. 2018 Jan 18;14(1):e1006798
pubmed: 29346420
Thorax. 2017 Dec;72(12):1104-1112
pubmed: 28280235
Eur Respir J. 2017 Nov 16;50(5):
pubmed: 29146601
Pediatr Pulmonol. 1999 Nov;28(5):321-8
pubmed: 10536062
Ann Intern Med. 2014 Aug 19;161(4):233-41
pubmed: 25133359
N Engl J Med. 2013 May 23;368(21):1963-70
pubmed: 23692169
PLoS One. 2016 Dec 8;11(12):e0167649
pubmed: 27930727
PLoS One. 2015 Apr 08;10(4):e0124124
pubmed: 25853698
Ann Am Thorac Soc. 2017 Oct;14(10):1548-1555
pubmed: 28708417
J Pediatr. 2009 Nov;155(5):623-8.e1
pubmed: 19616787
J Pediatr. 2009 Feb;154(2):183-8
pubmed: 18822427
Pediatrics. 2016 Apr;137(4):
pubmed: 27009033
Bioinformatics. 2013 Dec 1;29(23):3100-1
pubmed: 24021386
Lancet Respir Med. 2016 Aug;4(8):627-635
pubmed: 27180018